DeGolyer Donald W sold $126K of EBS

DeGolyer Donald W sold 17,800 shares of Emergent BioSolutions Inc. (EBS) at $7.09 ($0.13M total) on 2026-10-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DeGolyer Donald W
Published Oct 7, 2026, 7:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 7:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EBS
Bearish
high confidence
Mentioned
$EBS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EBSBearishLow
01

Why it matters

The disclosed sale is modest in size and may generate slight short‑term pressure on the stock, but is unlikely to move the market significantly.

02

Market read

Primary insider sale filing; modest relevance for traders monitoring EBS.

03

What to watch

The director's sale was pre‑arranged under a 10b5‑1 plan, reducing the informational content of the trade.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction by a director of Emergent BioSolutions.

Company-level read

Ticker impact

$EBSBearishHigh confidence
Context

Director DeGolyer sold 17,800 shares for $126,202 via a 10b5-1 plan, reducing his stake to 111,921 shares.

Expected impact

likely slight downward pressure as the market prices the insider sale

Evidence & confidence

Form 4 filings are primary source; a director selling $126k is a tangible sell signal, though the amount is modest.

Market effects

Minimal impact on the broader biotech sector; insider sales are routine.

No regional effect beyond the company's stock.

Limited to investors tracking EBS.

Counterpoint

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • Emergent BioSolutions Inc.

    Biopharmaceutical company whose director sold shares.

  • DeGolyer Donald W

    Director of Emergent BioSolutions executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)